Division of Pulmonary, Critical Care, and Sleep Medicine, The Ohio State University Wexner Medical Center, Columbus, Ohio.
University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.
J Clin Sleep Med. 2022 Sep 1;18(9):2167-2172. doi: 10.5664/jcsm.10068.
Untreated obstructive sleep apnea (OSA) is associated with excessive daytime sleepiness, decreased quality of life, and cardiovascular disease. Positive airway pressure is the first-line therapy for OSA; however, adherence is difficult. Upper airway stimulation is a Food and Drug Administration-approved treatment of OSA. The objective of this study was to evaluate for a difference in treatment efficacy and adherence of upper airway stimulation therapy for OSA between individuals who are White and non-White using data from the ADHERE registry.
ADHERE registry is a multicenter prospective study of real-world experience of upper airway stimulation for treatment of OSA in the United States and Europe. Propensity score matching was used to create a balanced dataset between the White and non-White groups. -Tests at a significance level of 5% were used to compare numeric values between groups.
There were 2,755 participants of the ADHERE registry: 27 were excluded due to not having a race identified, 125 participants identified as non-White, 2,603 identify as White, and 27 did not provide race information. Propensity score matching was used to select 110 participants, with 55 White and 55 non-White for the noninferiority analysis. We did not find a difference in adherence, treatment apnea-hypopnea index, changes in Epworth Sleepiness Scale score, or clinical global impression after intervention score between White and non-White individuals.
Our study found that there was no statistically significant difference in adherence or efficacy with upper airway stimulation therapy between White and non-White individuals. However, the percent of non-White people implanted is low, which suggests a need to expand access to this therapy for non-White populations with OSA who cannot tolerate positive airway pressure therapy.
Khan M, Stone A, Soose RJ, et al. Does race-ethnicity affect upper airway stimulation adherence and treatment outcome of obstructive sleep apnea? . 2022;18(9):2167-2172.
未经治疗的阻塞性睡眠呼吸暂停(OSA)与日间嗜睡、生活质量下降和心血管疾病有关。正压通气是 OSA 的一线治疗方法;然而,患者的依从性很差。上气道刺激是美国食品和药物管理局批准的 OSA 治疗方法。本研究的目的是利用 ADHERE 登记处的数据,评估白种人和非白种人患者在上气道刺激治疗 OSA 的疗效和依从性是否存在差异。
ADHERE 登记处是一项多中心前瞻性研究,研究了美国和欧洲使用上气道刺激治疗 OSA 的真实世界经验。使用倾向评分匹配在白种人和非白种人组之间创建一个平衡数据集。在 5%的显著性水平下使用 t 检验比较组间的数值。
ADHERE 登记处共有 2755 名参与者:27 名因未识别种族而被排除,125 名参与者被确定为非白种人,2603 名确定为白种人,27 名未提供种族信息。使用倾向评分匹配选择了 110 名参与者,其中 55 名白种人和 55 名非白种人进行非劣效性分析。我们没有发现白种人和非白种人之间的依从性、治疗呼吸暂停低通气指数、Epworth 嗜睡量表评分变化或干预后临床总体印象评分存在差异。
我们的研究发现,白种人和非白种人在上气道刺激治疗的依从性或疗效方面没有统计学上的显著差异。然而,植入的非白种人比例较低,这表明需要为不能耐受正压通气治疗的 OSA 非白种人群扩大获得这种治疗的机会。
Khan M, Stone A, Soose RJ, et al. Does race-ethnicity affect upper airway stimulation adherence and treatment outcome of obstructive sleep apnea?. 2022;18(9):2167-2172.